Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes

Authors:

Abstract
Most younger patients with acute myeloid leukemia (AML) can achieve complete remission (CR) with induction chemotherapy.1 After CR, further postremission treatment (PRT) would be necessary to prevent relapse.2 Postremission treatment usually consists of either a stem cell transplant (SCT) or cytarabine-based consolidation chemotherapy. Allogeneic SCT (allo-SCT) is generally accepted as the most effective PRT to prevent relapse, but it has relatively high rates of transplant-related mortality.3 Autologous SCT (auto-SCT) and chemotherapy carry a lower risk of transplant-related mortality compared with allo-SCT.4 However, this lower risk of transplant-related mortality is offset by a higher risk of relapse owing to the lack of a graft-vs-leukemia effect and the potential infusion of leukemia cells in grafts.5,6 Currently, decisions for PRT depend mainly on risk stratification based on cytogenetics and molecular markers,2,7 but it remains controversial, particularly for patients with intermediate-risk AML (IR-AML).3-6,8-13 For instance, some studies have suggested that a survival benefit is associated with the use of allo-SCT in patients with IR-AML,3,5,6 whereas other studies have showed that auto-SCT or chemotherapy had no significant survival differences compared with allo-SCT.4,12,13 Thus, these studies highlight the need to find additional factors associated with survival outcomes that optimize PRT choices for patients with IR-AML.

This publication has 49 references indexed in Scilit: